Les adolescents et les jeunes adultes (AJA) atteints de cancer ont des besoins spécifiques par rapport aux autres groupes d'âge et l’accès aux soins palliatifs pour ce groupe d'âge demeure difficile.

Morgan Stanley & Co. LLC, Leerink Partners, BofA Securities and Cantor are acting as joint active book-running managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the ...

Drugstore, the parent company of eDrugstore.com, a leading U.S.-based telemedicine and online pharmacy platform, today announced a strategic partnership with Groupon for exclusive Black Friday and ...

The presentation slides and a link to the live and archived webcast will also be available on the Events & News – Events page of Jasper's Investor Relations website.

Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer ...

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference ...

Macrilen ® (macimorelin), COSCIENS’ lead pharmaceutical product, is a ghrelin agonist that stimulates the secretion of growth hormone from the pituitary gland and is the first and only U.S. Food and ...

Belite Bio intends to use the net proceeds of the offering for (i) commercialization preparation, including building our in-house commercialization team, establishing sales network and systems, and ...

Under Nasdaq rules, the Company now has 60 calendar days to submit a plan to regain compliance and if such plan is accepted by Nasdaq, an exception of up to 180 calendar days from the original ...

PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer ...

According to IQVIA ® U.S. annual sales for cyclosporine ophthalmic emulsion 0.05% in sterile, preservative-free single-use vials for the 12 months ended September 2025 were approximately $2.0 billion.

Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral presentation of ...